On June 18th, Gelonhui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Montelukast Sodium Chewable Tablets. Montelukast sodium chewable tablets are used for the prevention and long-term treatment of asthma in children aged 2-14, including the prevention of daytime and nighttime asthma symptoms, the treatment of aspirin-sensitive asthma patients, the prevention of exercise-induced bronchoconstriction, and the relief of symptoms caused by allergic rhinitis (seasonal and perennial allergic rhinitis in children aged 2-14).
葫芦娃(605199.SH)：获得孟鲁司特钠咀嚼片药品注册证书
Hainan Huluwa Pharmaceutical Group (605199.SH) has obtained the registration certificate of Montelukast Sodium Chewable Tablets.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.